Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lomustine-Temozolomide Combination Therapy Versus Standard Temozolomide in Methylated MGMT Promoter Glioblastoma
NCT05095376Phase 3Active, not recruiting
- Sponsor
- NRG Oncology
- Start
- Mar 2022
- Primary completion
- Feb 2026
- Modality
- DNA Intercalators/Alkylators
- Countries
- 2
01
Overview
A Phase 3 trial of lomustine in glioblastoma (GBM), Gliosarcoma (GS), sponsored by NRG Oncology. Started Mar 2022; status: active, not recruiting.
02
Drugs
lomustine
03
Conditions
glioblastoma (GBM)Gliosarcoma (GS)
Beyond the preview
Go deeper on NCT05095376.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05095376.